Hanne Damgaard Jensen
Geschäftsführer bei CURASIGHT A/S
Vermögen: 6 292 $ am 31.03.2024
Profil
Hanne Damgaard Jensen is currently the Chief Executive Officer at ROS-Therapeutics ApS, Chairman at Aimvion A, and Chief Operating & Development Officer at Curasight A.
Previously, she was the Chief Executive Officer at Azanta A from 2009 to 2017, a Project Manager at Novo Nordisk A from 1995 to 1999, and a Senior Vice President-Drug Development at Genmab A from 1999 to 2007.
She also held positions at Johnson & Johnson and Roche Innovation Center Copenhagen A.
Ms. Jensen holds an MBA from Copenhagen Business School and Scandinavian International Management Institute, and a graduate degree from the University of Copenhagen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CURASIGHT A/S
0,02% | 31.12.2022 | 3 979 ( 0,02% ) | 6 292 $ | 31.03.2024 |
Aktive Positionen von Hanne Damgaard Jensen
| Unternehmen | Position | Beginn |
|---|---|---|
| CURASIGHT A/S | Geschäftsführer | 01.01.2022 |
| ROS-Therapeutics ApS | Vorstandsvorsitzender | 01.01.2018 |
Aimvion A/S
 Aimvion A/S Pharmaceuticals: MajorHealth Technology Aimvion A/S provides services for autoimmune diseases and biotechnology. The private company is based in Copenhagen, Denmark. | Vorsitzender | 01.01.2020 |
Ehemalige bekannte Positionen von Hanne Damgaard Jensen
| Unternehmen | Position | Ende |
|---|---|---|
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Vorstandsvorsitzender | 01.01.2017 |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Corporate Officer/Principal | 01.01.2008 |
| GENMAB A/S | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | 01.01.1999 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Ausbildung von Hanne Damgaard Jensen
| Copenhagen Business School | Masters Business Admin |
| University of Copenhagen | Graduate Degree |
| Scandinavian International Management Institute | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| GENMAB A/S | Health Technology |
| CURASIGHT A/S | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Azanta A/S
Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Health Technology |
Aimvion A/S
Aimvion A/S Pharmaceuticals: MajorHealth Technology Aimvion A/S provides services for autoimmune diseases and biotechnology. The private company is based in Copenhagen, Denmark. | Health Technology |
| ROS-Therapeutics ApS |
